BusinessOcera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver FailureBy Nasdaq OMXSep 21, 2016, 8:05 PM UTC
BusinessOcera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)By Nasdaq OMXApr 15, 2016, 1:05 PM UTC
BusinessOcera to Present at the 15th Annual Needham Healthcare ConferenceBy Nasdaq OMXApr 5, 2016, 8:25 PM UTC
BusinessOcera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 3, 2016, 2:05 PM UTC
BusinessOcera to Present at the Cowen and Company 36th Annual Health Care ConferenceBy Nasdaq OMXFeb 29, 2016, 9:05 PM UTC
BusinessKannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HEBy Nasdaq OMXFeb 29, 2016, 2:00 PM UTC
BusinessKannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”By Nasdaq OMXFeb 16, 2016, 4:16 PM UTC
BusinessKannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”By Nasdaq OMXFeb 16, 2016, 4:16 PM UTC
